Allergan Inc.: PharmaVitae Report

Report Summary

This analysis examines the historical and forecast performance for Allergan in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs

Features and benefits

• Gain insight into Allergan's strategic outlook across the next 6 years
• Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source

Highlights

Allergan's prescription sales will experience positive year-on-year growth rates until sales turn to decline following key patent expiries in 2014. Although generic erosion of Allergan's ophthalmic franchise will drive a decline in revenues, gains generated by uptake of Botox will offset these negative trends leading to positive growth overall.

Table of Contents

EXECUTIVE SUMMARY
Key findings
Allergan prescription pharma sales outlook
Allergan financial outlook
Key developments
(Untitled sub-section)
Upcoming developments
SWOT analysis
(Untitled sub-section)
Weaknesses
Opportunities
Threats
STRATEGIC INSIGHT
Key findings
Expansion of Botox indications shaped Allergan’s strategy and growth trajectory
High reliance on Botox
COMPANY INTRODUCTION
Key findings
Background
Key corporate developments
M&A history
Acquired by SmithKline Beckman
Allergan spun-out from SmithKline Beckman
Acquisition of Oculinum
Divestment of Allergan Humphrey
Divestment of contact lens businesses
Five acquisitions were made in and around 1995
Allergan Specialty Therapeutics spun-out
Allergan Specialty Therapeutics re-acquired
Bardeen Sciences set up
Advanced Medical Optics spun-out
Bardeen Sciences acquired
Oculex acquired
Acquisition of Inamed
Groupe Corneal Laboratoires acquired
EndoArt acquired
Acquisition of Esprit Pharma
Acquisition of Serica Technologies
Acquisition of Vicept Therapeutics
Current corporate structure
Pharmaceuticals
Allergan Medical
SALES ANALYSIS
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2004–16
Product analysis
Product analysis, 2004–10
Product analysis, 2010–16
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2010–16
Core analysis, 2010–16
Expiry analysis, 2010–16
Launch/core/expiry configuration, 2010–16
Molecule type analysis
Externalization analysis
FINANCIAL ANALYSIS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2004–10
Operating costs and profit analysis
Operating costs and profit analysis, 2004–10
Operating cost ratio and profit margin analysis, 2004–10
Operating cost ratio and profit margin analysis, 2010–16
Operating costs and profit analysis, 2010–16
PRODUCT ANALYSIS
Overview
Botox
Restasis
Lumigan
Alphagan
Allergan pipeline overview
APPENDIX
References
Exchange rates

List of Tables

Table: Allergan key product overview ($m), 2010–16
Table: Allergan financial performance ($m), 2010–16
Table: Allergan product portfolio overview ($m), 2004–10
Table: Allergan product portfolio overview ($m), 2010–16
Table: Allergan prescription pharmaceutical sales, by therapy area ($m), 2010–16
Table: Allergan prescription pharmaceutical sales, by geographic region ($m), 2010–16
Table: Allergan launch portfolio overview ($m), 2010–16
Table: Allergan core portfolio overview ($m), 2010–16
Table: Allergan expiry portfolio overview ($m), 2010–16
Table: Allergan prescription pharmaceutical sales, by molecule type ($m), 2010–16
Table: Allergan prescription pharmaceutical sales, by source ($m), 2010–16
Table: Total Allergan sales, by business unit ($m), 2004–10
Table: Allergan operating revenues, costs, and profit ($m), 2004–10
Table: Allergan operating cost ratios and profit margin (as a percentage of total revenues), 2004–10
Table: Allergan operating cost ratios and profit margin (as a percentage of total revenues), 2010–16
Table: Allergan operating revenues, costs, and profit ($m), 2010–16
Table: Key product sales ($m), 2010–16
Table: Botox : overview
Table: Botox: sales forecast ($m), 2010–16
Table: Restasis : overview
Table: Restasis: sales forecast ($m), 2010–16
Table: Lumigan : overview
Table: Lumigan: sales forecast ($m), 2010–16
Table: Alphagan : overview
Table: Alphagan: sales forecast ($m), 2010–16
Table: Allergan’s R&D pipeline
Table: Exchange rates, 2011

List of Figures

Figure: The PharmaVitae Explorer
Figure: Allergan prescription pharmaceutical performance, sales ($m) and growth rate (%), 2004–16
Figure: Allergan’s financial performance ($m), 2004–16
Figure: FDA-approved Botox indications
Figure: The central role of Botox in Allergan’s strategic moves
Figure: Allergan prescription pharmaceutical sales ($m), 2004–16
Figure: Allergan’s M&A history
Figure: Current corporate structure
Figure: Allergan prescription pharmaceutical performance, sales ($m) and growth rate (%), 2004–16
Figure: Allergan’s key product sales ($m), 2004–16
Figure: Allergan key sales growth drivers and resistors ($m), 2004–10
Figure: Allergan key sales growth drivers and resistors ($m), 2010–16
Figure: Allergan prescription pharmaceutical sales, by therapy area ($m), 2004–16
Figure: Allergan prescription pharmaceutical sales, by geographic region ($m), 2004–16
Figure: Allergan launch/core/expiry configuration ($m), 2010–16
Figure: Allergan prescription pharmaceutical sales, by molecule type ($m), 2004–16
Figure: Allergan prescription pharmaceutical sales, by source ($m), 2004–16
Figure: Allergan operating revenues, costs, and profit ($m), 2004–16
Figure: Botox sales, by geographic region ($m), 2004–16
Figure: Restasis sales, by geographic region ($m), 2004–16
Figure: Lumigan sales, by geographic region ($m), 2004–16
Figure: Alphagan sales, by geographic region ($m), 2004–16
Figure: Allergan’s pipeline, by therapy area